#United States #Lexington #Curis #emavusertib #CA-4948

Curis, Inc. Plans to Announce Third Quarter 2026 Financial Results

Curis, Inc. (NASDAQ: CRIS), a prominent biotechnology firm, has officially scheduled its financial and operational report for the third quarter of 2026. This announcement comes on the heels of significant advancements in the company's flagship drug, emavusertib (CA-4948), which targets IRAK4 and FLT3 pathways, marking an important step in Curis's ongoing research and development efforts.

Event Details

On November 12, 2026, at 4:00 PM ET, Curis will release its financial results, providing insights into the company’s performance and future prospects. Following this, at 4:30 PM ET, management will host a conference call and a live webcast to discuss the results in detail. This dual approach allows for a robust interaction with stakeholders, showcasing Curis's transparency and commitment to its investors.

Those interested in participating can dial in using the following numbers:

• - United States: (800) 836-8184
• - International: (646) 357-8785.

For those who prefer, a live audio webcast is accessible through the Curis website. Additionally, a replay of the call will be made available shortly after, ensuring that all investors have the opportunity to engage with the company's updates.

Company Overview

Curis, Inc. is at the forefront of biotechnology innovation, primarily focused on developing emavusertib, an oral small-molecule inhibitor. Current studies include the TakeAim Lymphoma Phase 1/2 trial, which evaluates emavusertib in combination with Ibrutinib for patients grappling with relapsed or refractory primary central nervous system lymphoma (PCNSL). Another significant trial is the TakeAim CLL Phase 2 study assessing emavusertib alongside Zanubrutinib for chronic lymphocytic leukemia (CLL) patients.

Notably, Curis has achieved substantial progress with its monotherapy and combination studies in acute myeloid leukemia (AML), leading to expectations of continued funding and research into emavusertib’s efficacy in treating AML. Moreover, the drug has received Orphan Drug Designation from the U.S. FDA for the treatment of PCNSL, AML, and MDS, alongside designation from the European Commission for PCNSL.

Importance of this Announcement

The third quarter financial results will serve as a crucial indicator of Curis’s financial health and operational capabilities amidst a competitive market landscape. Investors and analysts alike are keen to glean insights into the potential growth trajectories of emavusertib, particularly as Curis continues to advance its clinical trials.

This announcement reflects Curis's strategic focus on innovation and patient care within the biotechnology sector. By actively engaging with investors during this quarterly review, Curis demonstrates its dedication to transparency and ongoing communication, which is vital for sustaining investor confidence and interest.

For further details and the latest updates, interested parties are encouraged to visit Curis's official website at www.curis.com. The company's commitment to developing groundbreaking therapies continues to position it as a leader in the biotechnology field.

Curis, Inc.'s diligent focus on emavusertib’s development not only aims to address unmet medical needs but also encompasses a broader vision of improving patient outcomes in oncology. As we await the forthcoming financial results, the anticipation surrounding emavusertib's potential realization in the market continues to grow.